orphan products extension now accelerating cures and treatments act of 2017 or the open act this bill amends the federal food , drug , and cosmetic act to require the department of health and human services ( hhs ) to extend by six months the exclusivity period for a drug or biological product approved by the food and drug administration ( fda ) when the product is additionally approved to prevent , diagnose , or treat a new indication that is a rare disease or condition ( also known as an orphan disease ) .
hhs may revoke an extension if the application submitted to the fda for the new indication contained an untrue material statement .
hhs must notify the public of products that receive this extension and patents related to those products .
products may receive only one extension under this bill .
extensions under this bill are in addition to other extensions .
the bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition .